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Figure 3: The collagen network in cervical tissue in a non-pregnant woman. The plane of this image 
is perpendicular to the longitudinal direction of the endocervical canal. (From Myers K et al. 
Changes in the biochemical constituents and morphologic appearance of the human cervical 
stroma Sduring pregnancy. Eur J Obstet Gynecol 2009;S82- 89). 
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Figure 5: Synthesis of the five principal prostaglandins from arachidonic acid. (From: 
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Figures 6 and 7: Electron micrographs of cervical tissue showing (left) intact well organised 
collagen fibrils and (right) disorganised collagen framework indicating disintegration of the collagen 
fibrils following treatment with misoprostol. (From Radulovic et al. Cervical priming in the first 
trimester: morphological and biochemical effects of misoprostol and isosorbide mononitrate. Acta 
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Figure 9: Mean plasma concentrations of misoprostol acid over time with oral and vaginal 
administration. (From: Zieman et al. Absorption kinetics of misoprostol with oral or vaginal 
administration. Obstet Gynecol 1997;90:88-92). 

%
Figure 10: Mean plasma concentrations of misoprostol acid over time with oral, rectal and 
vaginal administration. (From: Khan et al. Oral, rectal, and vaginal pharmacokinetics of 
misoprostol. Obstet Gynecol 2004;103:866-870). 
Figure 11: Mean plasma concentrations of misoprostol acid over time with sublingual, oral, vaginal 
and vaginal + water administration. (From Tang et al. Pharmacokinetics of different routes of 
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